Mike Patterson CEO graphenefrontiers.com Market Opportunity $9.9B - - PowerPoint PPT Presentation

▶
mike patterson ceo
SMART_READER_LITE
LIVE PREVIEW

Mike Patterson CEO graphenefrontiers.com Market Opportunity $9.9B - - PowerPoint PPT Presentation

Oct 31, 2023 50 likes •402 views

Mike Patterson CEO graphenefrontiers.com Market Opportunity $9.9B Biosensors: 1st Gen POC Diagnostics: Not Good Enough Limited sensitivity Slow Inaccurate ELISA GFET 100x- 1000x better Limit of Detection (LOD) 1-20pg/ml

slide-1
SLIDE 1

Mike Patterson – CEO

graphenefrontiers.com

slide-2
SLIDE 2

Market Opportunity

slide-3
SLIDE 3

Biosensors:

$9.9B

slide-4
SLIDE 4
  • Limited sensitivity
  • Slow
  • Inaccurate

1st Gen POC Diagnostics: Not Good Enough

slide-5
SLIDE 5

ELISA GFET Limit of Detection (LOD) 1-20pg/ml 100x-1000x better than ELISA Ability to Multiplex No (1 antibody per run) Yes Speed May take hours for incubation and processing Sample to results in minutes Cost Expensive Optical Readers All electronic, lower cost Ease of Use Trained Lab Tech Needed After sample obtained, the rest is automated Specificity of detection Relies on secondary detection antibody Higher false positives Specific and direct detection – all electronic

slide-6
SLIDE 6

Next Gen POC Diagnostics: Quantum Leap

slide-7
SLIDE 7

How it Works

slide-8
SLIDE 8

Devices: GFET

GFET = Graphene Field Effect Transistor

slide-9
SLIDE 9
slide-10
SLIDE 10
slide-11
SLIDE 11
slide-12
SLIDE 12

Why Graphene?

slide-13
SLIDE 13
slide-14
SLIDE 14

Conductive

Heat Electricity

slide-15
SLIDE 15

Impermeable and Hydrophobic

slide-16
SLIDE 16

But will it scale?

slide-17
SLIDE 17

Problem: Commercial Production

1) Low Volume 2) Expensive 3) Not Uniform 4) Harsh Chemicals

slide-18
SLIDE 18

08

Breakthrough: Problem Solved

slide-19
SLIDE 19
slide-20
SLIDE 20

2010 1 cm 2 > $10,000

slide-21
SLIDE 21

2012 1 cm 2 < $10

slide-22
SLIDE 22

2015 1 cm 2 < $.01

slide-23
SLIDE 23
slide-24
SLIDE 24

Evidence and Traction

slide-25
SLIDE 25
  • IL-6
  • Borrelia burgdorferi
  • Osteopontin (OPN)
  • Salmonella

Demonstrated Results: Multiple Proteins

Clear signal @ 1pg/mL (30 fM)

slide-26
SLIDE 26

Proof of Concept Program: Troponin I

slide-27
SLIDE 27

POC Diagnostics: Potential Partners

slide-28
SLIDE 28

18

Team Graphene: Founders

A.T. Charlie Johnson, Ph.D. – Founder, Advisor Mike Patterson – Chief Executive Officer

slide-29
SLIDE 29

18

Bruce Willner – Chief Science Officer

slide-30
SLIDE 30

18

Team Graphene – Product Team

Ryan Mendoza

  • Electrical

Engineering Victoria Tsai, Ph.D.

  • Neuroscience
  • Clinical Research

Paige Boehmcke

  • Materials Science

NOW HIRING:

  • Diagnostics Expert
  • Commercialization

experience

slide-31
SLIDE 31

19

Strong: Intellectual Property

Core Patents Status (3):

  • 2010 PCT, U. Penn, Woodcock Washburn
  • Exclusive, all fields perpetual licenses
  • Global, w/sublicense rights
  • National Phase: US, EU, Korea, Japan, China, India
  • 2 x 2010 US Utility applications

Additional IP (5):

  • Patent pending transfer method
  • Additional, complementary sensor IP under option
slide-32
SLIDE 32

Grants Awarded to Date: $1,285,000

slide-33
SLIDE 33

22

Equity Capital: Existing Funding

2012 seed round: $426,000 (common equity)

Management Individual Angels

slide-34
SLIDE 34

23

Capital Needs: Open Financing

$1,200,000 convertible securities

  • $731,000 closed to date

Uses:

  • Troponin I Proof of Concept Program:
  • Diagnostics expert (new hire)
  • Capital Equipment
  • Sensor production
slide-35
SLIDE 35

Mike Patterson - CEO mike@graphenefrontiers.com (267) 223-5051